Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest

Fig. 4

Patient case studies. (A) Clinical course of patient #1 and timing of blood sampling over the course of his treatment. (B) Liquid biopsies and blood markers at two time points: PSA value, CTC numbers, AR-V7 results from both the VTX-1-AdnaDetect assay and the Oncotype DX AR-V7 Nucleus Detect test. (C) Side-by-side comparison of the AR-V7 results for three blood samples from 2 patients between the VTX-1-AdnaDetect assay and the Oncotype DX AR-V7 Nucleus Detect test. PC: prostate cancer; PSA: prostate-specific antigen; CTC: circulating tumor cell; AR-V7: androgen receptor splice variant 7; cfRNA: cell-free RNA.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us